Abstract: | Objective: To observe the efficacy and safety of the Mongolian medicine new Hesugawurile in the treatment of depression after ischemic stroke. Methods: A total of 100 outpatients and inpatients in the Inner Mongolia International Mongolian Hospital were selected from March 2020 to May 2021. Patients who met the inclusion criteria were randomized into experimental and control groups with 50 cases each; both groups were given the basic treatment of ischemic stroke. On this basis, the experimental group was given the Mongolian medicine new Hesugawurile, and the control group was given the western medicine Deanxit (Flupentixol and meritroxine tablets); Ratings of the Hamilton Depression Scale (HAMD-17), the Self-rated Depression Scale (SDS), and the Activity of Daily Life (ADL) were compared before and after treatment. Results: The total efficiency was 88% and 76% in controls, and statistically significant (P<0.05).After treatment, the HAMD-17 and SDS scale scores decreased in both groups, with the experimental group scoring lower than the control group, with statistically significant differences (P<0.05). The ADL scale scores of the two groups were improved after treatment, and the score of the experimental group was higher than that of the control group, the difference was statistically significant (P<0.05). Before and after treatment, the blood and urine routine, liver function, renal function, electrocardiogram and other safety tests were performed in the two groups. There was no abnormality, and no discomfort symptoms and no adverse reactions occurred during the medication. Conclusion: The Mongolian medicine new Hesugawurile has significant clinical efficacy in the treatment of depression after ischemic stroke. The improvement of depression and the recovery of activities of daily living are significantly better than those in the control group, which is worthy of clinical application. |